Navigation Links
Aware, Inc. Reports Third Quarter 2008 Financial Results

BEDFORD, Mass., Oct. 23 /PRNewswire-FirstCall/ -- Aware, Inc. (Nasdaq: AWRE), a leading supplier of broadband technology and biometrics software, today reported financial results for its third quarter ended September 30, 2008.

Revenues for the third quarter of 2008 were $6.4 million, a decrease of 14% compared to $7.5 million in the same quarter last year. For the nine months ended September 30, 2008, revenues decreased 6% to $18.4 million, compared to $19.7 million in the same period a year ago.

The Company reports its net income and basic and diluted net income per share in accordance with U.S. generally accepted accounting principles (GAAP), and additionally, on a non-GAAP basis. Non-GAAP net income, where applicable, excludes the effect of stock-based compensation expense. The company uses the non-GAAP information internally to evaluate its operating performance and believes these non-GAAP measures are useful to investors as they provide additional insight into the underlying operating results. However, non-GAAP measures are not stated in accordance with, should not be considered in isolation from, and are not a substitute for, GAAP measures. A reconciliation of GAAP to non-GAAP results has been provided in the attached financial tables.

The GAAP net loss for the third quarter of 2008 was $0.7 million, or $0.03 per diluted share, which included $0.4 million of stock-based compensation charges in accordance with the provisions of FAS 123(R). This compared to GAAP net income of $1.0 million, or $0.04 per diluted share, for the same period a year ago. GAAP net loss for the nine months ended September 30, 2008 was $3.2 million, or $0.13 per share, compared to a net loss of $32,000, or $0.00 per share, for the same period a year ago.

The Non-GAAP net loss for the third quarter of 2008, excluding the effect of stock-based compensation, was $0.3 million, or $0.01 per diluted share. For the nine months ended September 30, 2008, the company had a non-GAAP net loss, excluding the effect of stock-based compensation, of $2.1 million, or $0.09 per share.

Michael Tzannes, Aware's chief executive officer, said, "Biometrics revenues this quarter were again strong, driven by exposure to multiple segments of the biometrics market through a broad base of OEM and system integrator customers. In DSL Test and Diagnostics, we continue to make progress with test infrastructure opportunities driven by the deployment of VDSL2 and IPTV services. Our OEM customer base positions us well in multiple markets. In licensing, our strategy is to leverage our world class silicon intellectual property technology base, and diversify into new revenue opportunities."

Note: Aware's conference call will be broadcast live over the Internet today, October 23, 2008 at 5:00 p.m. Eastern Time. To listen to the call, please go to The conference call may also be heard by calling 719-325-4919 and referencing the confirmation number 4405951. A replay of the call will be archived on our website after the call.

About Aware

Aware is a leading technology and software supplier for the telecommunications and biometrics industries. For more than ten years, Aware has pioneered innovations at telecommunications standards-setting organizations and continues to develop and market DSL silicon intellectual property and test and diagnostics products. Its StratiPHY(TM) IP product line supports DSL standards, including ADSL2+ and VDSL2, and has been broadly licensed to leading semiconductor companies. Telecom equipment vendors and phone companies use Aware's DSL test and diagnostics modules and Dr. DSL(R) software to help provision DSL circuits globally. Aware is also a veteran of the biometrics industry, providing biometric and imaging software components used in government systems worldwide since 1992. Aware's interoperable, standard-compliant, field-proven imaging products are used in a number of applications, from border management to criminal justice to medical imaging. Aware is a publicly held company (Nasdaq: AWRE) based in Bedford, Massachusetts.

Safe Harbor Warning

Portions of this release contain forward-looking statements regarding future events and are subject to risks and uncertainties, such as estimates or projections of future revenue and earnings and the growth of the DSL and biometrics markets. Aware wishes to caution you that there are factors that could cause actual results to differ materially from the results indicated by such statements. The DSL factors include, but are not limited to: we have a unique business model, our quarterly results are difficult to predict, our DSL licensing and DSL test and diagnostic businesses depend upon a limited number of customers, we derive a significant amount of revenue from a small number of customers, we depend on equipment companies to incorporate our technology into their products, we face intense competition from other DSL vendors, DSL technology competes with other technologies for broadband access, our business could be harmed if our test and diagnostic hardware and software products have quality problems, we depend on a single source contract manufacturer for the manufacture of our DSL hardware products, our manufacturing systems may not be adequate for our DSL test and diagnostics hardware products, we depend on single source suppliers for components in our DSL hardware products, and our business is subject to rapid technological change. The biometric factors include, but are not limited to: market acceptance of our biometric products, changes in contracting practices of government or law enforcement agencies, announcements or introductions of new products by our competitors, delays, failures or problems in our biometric products, problems in our biometrics services business, delays in the adoption of new industry biometric standards, and competitive pressures resulting in lower software product revenues. We refer you to the documents Aware files from time to time with the Securities and Exchange Commission, specifically the section titled Risk Factors in our annual report on Form 10-K for the fiscal year ended December 31, 2007 and other reports and filings made with the Securities and Exchange Commission.

Aware, StratiPHY, and Dr. DSL are trademarks or registered trademarks of Aware, Inc.



(In thousands, except per share data)


Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007


Product sales $3,939 $5,097 $11,811 $12,333

Contract revenue 2,014 1,851 5,313 5,260

Royalties 437 508 1,310 2,092

Total revenue 6,390 7,456 18,434 19,685

Costs and expenses:

Cost of product sales(1) 528 901 1,976 3,087

Cost of contract revenue(1) 1,365 1,553 3,512 4,315

Research and development(1) 2,945 2,528 9,984 7,735

Selling and marketing (1) 1,141 936 3,297 2,808

General and administrative(1) 1,315 1,009 3,793 3,269

Total costs and expenses 7,294 6,927 22,562 21,214

Income/(loss) from operations (904) 529 (4,128) (1,529)

Interest income 244 512 942 1,520

Income/(loss) before provision for

income taxes (660) 1,041 (3,186) (9)

Provision for income taxes 3 6 16 23

Net income/(loss) ($663) $1,035 ($3,202) ($32)

Net income/(loss) per share -

basic ($0.03) $0.04 ($0.13) ($0.00)

Net income/(loss) per share -

diluted ($0.03) $0.04 ($0.13) ($0.00)

Weighted average shares -

basic 23,510 23,757 23,753 23,710

Weighted average shares -

diluted 23,510 24,996 23,753 23,710

(1) Effective January 1, 2006 the Company adopted Statement of Financial

Accounting Standard No. 123 (Revised), "Share-Based Payment" (FAS

123(R)). The amounts in the tables above include stock-based

compensation as follows (in thousands):

Three Months Nine Months

Ended Ended

September 30, September 30,

2008 2007 2008 2007

Cost of product sales $3 $4 $9 $8

Cost of contract revenue 45 54 105 133

Research and development 136 127 463 311

Sales and marketing 52 32 133 78

General and administrative 161 88 405 262

Total stock-based compensation costs $397 $305 $1,115 $792


Non-GAAP Financial Measures and Reconciliation

(In thousands, except per share data)


Three Months Nine Months

Ended Ended

September 30, September 30,

2008 2007 2008 2007

GAAP net income/(loss) ($663) $1,035 ($3,202) ($32)

Stock-based compensation 397 305 1,115 792

Non-GAAP net income/(loss) ($266) $1,340 ($2,087) $760

Three Months Nine Months

Ended Ended

September 30, September 30,

2008 2007 2008 2007

GAAP net income/(loss) per share ($0.03) $0.04 ($0.13) $0.00

Stock-based compensation 0.02 0.01 0.04 0.03

Non-GAAP net income/(loss) per share ($0.01) $0.05 ($0.09) $0.03



(In thousands)


September December

30, 31,

2008 2007


Cash and investments $37,809 $38,549

Accounts receivable, net 4,366 7,661

Inventories, net 1,776 1,424

Property and equipment, net 7,621 7,872

Other assets, net 749 877

Total assets $52,321 $56,383


Total current liabilities $2,773 $2,817

Long-term deferred revenue 330 330

Total stockholders' equity 49,218 53,236

Total liabilities and stockholders' equity $52,321 $56,383

SOURCE Aware, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
2. Alexion Reports Third Quarter 2008 Results
3. Nuvasive Reports Third Quarter 2008 Financial Results
4. Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
5. NicOx Reports Results for the First Three Quarters of 2008
6. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
7. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
8. Amylin Pharmaceuticals Reports Third Quarter Financial Results
9. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
10. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
11. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
(Date:10/9/2017)... ... , ... At its national board meeting in North Carolina, ARCS® Foundation ... of Physics and Astronomy, has been selected for membership in ARCS Alumni Hall ... 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. ... to perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s ...
(Date:10/5/2017)... LINDA, CA (PRWEB) , ... October 05, 2017 , ... ... innovators, engineers, and scientists from around the world, is giving back to cancer research ... sold in October. , Now through October 31, shoppers can use promo code ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):